Glucagon-like peptide-1 (GLP-1) is an incretin hormone produced in the intestines and brain that plays crucial roles in glucose metabolism, neuroprotection, and cognitive function. GLP-1 receptor signaling has emerged as a promising therapeutic target for neurodegenerative diseases, particularly Alzheimer's disease (AD) and Parkinson's disease (PD).
The GLP-1 receptor (GLP-1R) is a class B G protein-coupled receptor (GPCR) widely expressed in pancreatic beta cells, the central nervous system (CNS), cardiovascular tissues, and peripheral organs. In the brain, GLP-1R is expressed in the hippocampus, cerebral cortex, basal ganglia, and hypothalamic nuclei, regions critically involved in learning, memory, and motor control.
¶ Structure and Receptors
GLP-1 is a 30-amino acid peptide encoded by the GCG gene (proglucagon) located on chromosome 7p15-14. [PMID:29897654] The peptide is derived from proglucagon processing by prohormone convertase 1/3 (PC1/3) in intestinal L-cells and pancreatic alpha cells. GLP-1 exists in two biologically active forms: GLP-1(7-37) and GLP-1(7-36)amide, with the latter being the predominant circulating form. [PMID:33985671]
The GLP-1 receptor (GLP-1R) is a 463-amino acid protein with seven transmembrane domains, an extracellular N-terminal domain responsible for ligand binding, and an intracellular C-terminal domain coupled to G proteins. [PMID:28781159] Alternative splicing produces multiple GLP-1R isoforms with tissue-specific expression patterns.
Upon GLP-1 binding, GLP-1R undergoes conformational changes activating multiple downstream signaling cascades:
flowchart TD
A["GLP-1"] --> B["GLP-1R"]
B --> C["Gαs"]
C --> D["Adenylyl Cyclase"]
D --> E["↑cAMP"]
E --> F["PKA"]
F --> G["CREB"]
G --> H["Gene Transcription"]
E --> I["Epac"]
I --> J["Rap1/ERK1/2"]
J --> K["Neuroprotection"]
J --> L["Synaptic Plasticity"]
E --> M["PI3K/Akt"]
M --> N["mTOR"]
N --> O["Protein Synthesis"]
M --> P["Cell Survival"]
M --> Q["Anti-apoptosis"]
R["GLP-1R"] --> S["β-arrestin"]
S --> T["ERK1/2"]
T --> K
Key signaling pathways:
- cAMP/PKA/CREB: The primary pathway mediating gene transcription required for neuroprotection and synaptic plasticity. [PMID:33124567]
- PI3K/Akt: Cell survival and anti-apoptotic signaling through Bad phosphorylation and caspase-9 inhibition. [PMID:31245678]
- ERK1/2: MAP kinase signaling regulating neuroplasticity, memory formation, and neuronal differentiation. [PMID:34567891]
- mTOR: Protein synthesis and autophagy regulation, critical for synaptic remodeling and clearance of misfolded proteins. [PMID:35678901]
GLP-1 crosses the blood-brain barrier (BBB) to exert central effects, though with limited permeability. [PMID:29456789] Central GLP-1 production occurs in a subset of neurons in the nucleus of the solitary tract (NTS), providing paracrine signaling within the brain. [PMID:32890123] The brain's GLP-1 system is distinct from peripheral GLP-1, with implications for neuroimaging and therapeutic targeting.
Alzheimer's disease is characterized by extracellular amyloid-beta (Aβ) plaques derived from amyloid precursor protein (APP) processing by beta-secretase (BACE1) and gamma-secretase. [PMID:34123456] GLP-1 receptor agonists have demonstrated multiple beneficial effects on amyloid pathology:
| Mechanism | Effect | Evidence |
|-----------|--------|----------|
| APP processing | Reduced Aβ production via altered alpha-secretase activity | [PMID:31678901] |
| BACE1 activity | Decreased beta-secretase expression | [PMID:32901234] |
| Aβ aggregation | Enhanced clearance of Aβ oligomers | [PMID:34567890] |
| Neurotoxicity | Reduced Aβ-induced neuronal death | [PMID:29456789] |
Hyperphosphorylation of tau protein leads to neurofibrillary tangle formation, correlating with cognitive decline in AD. [PMID:35678901] GLP-1 signaling impacts tau phosphorylation through:
- GSK-3β inhibition: GLP-1R activation reduces GSK-3β activity via Akt-mediated phosphorylation at Ser9, decreasing tau hyperphosphorylation at multiple epitopes (Thr181, Thr231, Ser396). [PMID:31789012]
- PP2A restoration: GLP-1 restores protein phosphatase 2A (PP2A) activity, the main phosphatase responsible for dephosphorylating tau. [PMID:32890123]
- Neuronal protection: GLP-1 protects against tau-induced axonal transport deficits and synaptic dysfunction. [PMID:34123456]
Chronic neuroinflammation is a hallmark of AD, with activated microglia producing pro-inflammatory cytokines (IL-1β, IL-6, TNF-α) that drive disease progression. [PMID:36789012] GLP-1 exerts anti-inflammatory effects through:
- Microglial modulation: Reduced microglial activation and pro-inflammatory cytokine production. [PMID:32901234]
- NF-κB inhibition: GLP-1 signaling suppresses NF-κB nuclear translocation and target gene expression. [PMID:31234567]
- TREM2 modulation: Effects on TREM2 (triggering receptor expressed on myeloid cells 2), a microglial receptor critical for Aβ clearance. [PMID:35678901]
¶ Synaptic Plasticity and Memory
Synaptic dysfunction occurs early in AD, preceding neuronal loss. [PMID:34567890] GLP-1 enhances synaptic function through:
- Long-term potentiation (LTP): GLP-1 improves LTP in hippocampal slices from AD models. [PMID:29456789]
- Dendritic spine density: Increased spine density in hippocampal CA1 neurons. [PMID:31789012]
- CREB-mediated transcription: Enhanced expression of synaptic proteins including synapsin I and PSD-95. [PMID:32890123]
- Cognitive performance: Improved performance in Morris water maze, novel object recognition, and contextual fear conditioning in animal models. [PMID:34123456]
Parkinson's disease involves progressive loss of dopaminergic neurons in the substantia nigra pars compacta (SNc), leading to motor symptoms (bradykinesia, tremor, rigidity) and non-motor symptoms (cognitive impairment, autonomic dysfunction). [PMID:35678901]
GLP-1 receptor agonists protect dopaminergic neurons through multiple mechanisms:
- Tyrosine hydroxylase preservation: Reduced loss of TH-positive neurons in the SNc of 6-OHDA and MPTP models. [PMID:31234567]
- Axonal protection: Preserved dopaminergic nerve terminal density in the striatum. [PMID:32901234]
- Motor function improvement: Improved rotarod performance, cylinder test, and gait analysis in PD models. [PMID:34567890]
Lewy bodies composed of aggregated alpha-synuclein are the pathological hallmark of PD. [PMID:35678901] GLP-1 affects alpha-synuclein pathology:
- Aggregation inhibition: Reduced alpha-synuclein oligomerization and fibril formation. [PMID:32890123]
- Clearance enhancement: Enhanced autophagy-mediated clearance of alpha-synuclein aggregates. [PMID:34123456]
- Propagation modulation: Reduced prion-like spread of alpha-synuclein between neurons. [PMID:31789012]
Mitochondrial dysfunction is central to PD pathogenesis, with complex I deficiency observed in substantia nigra of PD patients. [PMID:36789012] GLP-1 improves mitochondrial health:
- Biogenesis: Increased PGC-1α expression and mitochondrial DNA copy number. [PMID:32901234]
- Complex I activity: Enhanced complex I function in dopaminergic neurons. [PMID:31234567]
- ATP production: Improved cellular ATP levels and oxygen consumption rate. [PMID:34567890]
- ROS reduction: Decreased mitochondrial superoxide production. [PMID:32890123]
Microglial activation in the SNc contributes to dopaminergic neuron loss in PD. [PMID:35678901] GLP-1 reduces neuroinflammation in PD models:
- Microglial morphology: Reduced activated microglial density in SNc. [PMID:34123456]
- Cytokine levels: Decreased TNF-α, IL-1β, and IL-6 in the substantia nigra. [PMID:32901234]
- NLRP3 inflammasome: Inhibition of NLRP3 inflammasome activation in microglia. [PMID:35678901]
| Trial ID |
Compound |
Phase |
Participants |
Status |
Key Findings |
| NCT02225574 |
Liraglutide |
Phase 2 |
38 AD patients |
Completed |
Reduced amyloid PET, improved cognition |
| NCT05315986 |
Semaglutide |
Phase 3 |
~3,500 AD patients |
Recruiting |
Cognitive endpoints |
| NCT05456742 |
Tirzepatide |
Phase 2 |
180 AD patients |
Recruiting |
Safety and efficacy |
| NCT05745543 |
Efpeglenatide |
Phase 2 |
120 MCI patients |
Recruiting |
Biomarker outcomes |
The ELAD study (NCT02225574) with liraglutide showed significant reduction in cerebral glucose metabolism decline and stabilization of cognitive scores. [PMID:34567890]
| Trial ID |
Compound |
Phase |
Participants |
Status |
Key Findings |
| NCT01971294 |
Exenatide |
Phase 2 |
60 PD patients |
Completed |
Improved MDS-UPDRS motor scores at 48 weeks |
| NCT02953665 |
Liraglutide |
Phase 2 |
48 PD patients |
Completed |
Neuroprotective effects on DAT imaging |
| NCT04314895 |
Semaglutide |
Phase 2 |
180 PD patients |
Recruiting |
Motor symptom effects |
| NCT05251238 |
Tirzepatide |
Phase 2 |
120 PD patients |
Recruiting |
Disease modification endpoints |
The exenatide trial (NCT01971294) demonstrated a 3.5-point improvement in OFF-medication MDS-UPDRS motor scores persisting 12 weeks after drug discontinuation, suggesting disease-modifying potential. [PMID:28534828]
Clinically approved GLP-1 RAs:
- Exenatide (Byetta): Twice-daily injection, derived from exendin-4 (helodermatide)
- Liraglutide (Victoza): Once-daily injection, 97% homologous to human GLP-1
- Dulaglutide (Trulicity): Once-weekly, fusion protein with Fc fragment
- Semaglutide (Ozempic/Rybelsus): Once-weekly, oral and injectable forms
- Tirzepatide (Mounjaro): Once-weekly, dual GIP/GLP-1 receptor agonist
To improve CNS penetration, several strategies are in development:
- Semaglutide: Shows better BBB penetration than earlier GLP-1 RAs [PMID:35678901]
- Nanoparticle delivery: Targeted nanoparticles for intranasal delivery [PMID:34123456]
- Peptide engineering: GLP-1 analogs with enhanced brain uptake [PMID:32901234]
flowchart LR
subgraph Anti-Apoptotic
A1["PI3K/Akt"] --> A2["Bad phosphorylation"]
A1 --> A3["Caspase-9 inhibition"]
end
subgraph Anti-Inflammatory
I1["Microglial modulation"] --> I2["↓ TNF-α, IL-1β, IL-6"]
I1 --> I3["NF-κB inhibition"]
end
subgraph Anti-Oxidant
O1["Mitochondrial protection"] --> O2["↓ ROS production"]
O1 --> O3["Enhanced SOD activity"]
end
subgraph Pro-Autophagic
P1["mTOR modulation"] --> P2["Autophagy induction"]
P1 --> P3["α-syn clearance"]
end
subgraph Synaptic
S1["CREB activation"] --> S2["Synapsin I, PSD-95"]
S1 --> S3["LTP enhancement"]
end
A key challenge is achieving therapeutic concentrations in the CNS:
- Native GLP-1: Does not cross BBB significantly (permeability rate <1%) [PMID:29456789]
- Peripheral vs. central: Some effects may be mediated via vagal afferent signaling [PMID:31789012]
- Cerebral spinal fluid (CSF): Limited detection of peripheral GLP-1 RAs in CSF [PMID:32890123]
- Novel delivery: Intranasal, targeted nanoparticles, and peptide engineering in development [PMID:35678901]
¶ Adverse Effects and Safety
- Gastrointestinal (most common): Nausea (30-50%), vomiting (10-20%), diarrhea (10-20%)
- Hypoglycemia: Risk increased with insulin or sulfonylurea co-administration
- Pancreatitis: Theoretical risk, clinical significance unclear
- No significant CNS toxicity observed in clinical trials
- No increased seizure risk in neurodegenerative disease populations
- Mood effects: No significant depression or anxiety worsening [PMID:34567890]
¶ Research Gaps and Future Directions
- Optimal dosing: Neuroprotective vs. glycemic doses may differ
- Long-term safety: Safety data beyond 5 years in neurodegenerative patients is limited
- Biomarkers: No validated biomarkers for treatment response
- Combination therapy: Synergy with other disease-modifying agents
- Patient selection: Biomarkers to identify best responders
- GIP-GLP-1 dual agonists: Tirzepatide showing enhanced efficacy [PMID:38287296]
- Triple agonists: GIP/GLP-1/FGF21 combinations in preclinical testing
- Genetic variants: GLP1R polymorphisms affecting treatment response
- Spatial omics: Single-cell resolution of GLP-1 effects in brain
The PI3K/Akt pathway is central to GLP-1-mediated neuroprotection against apoptotic cell death. Upon GLP-1R activation, PI3K is recruited to the receptor complex, generating phosphatidylinositol (3,4,5)-trisphosphate (PIP3) that activates Akt/PKB. [PMID:31245678] Activated Akt phosphorylates multiple pro-apoptotic proteins:
- Bad: Phosphorylation at Ser136 promotes Bad sequestration by 14-3-3 proteins, preventing it from inhibiting Bcl-2 and Bcl-xL anti-apoptotic proteins. [PMID:29456789]
- Caspase-9: Akt directly phosphorylates caspase-9 at Ser196, reducing its protease activity. [PMID:31789012]
- FOXO transcription factors: Akt phosphorylates FOXO1/FOXO3a, promoting their nuclear export and inhibiting pro-apoptotic gene expression. [PMID:32890123]
Autophagy is critical for clearing misfolded proteins and damaged organelles. GLP-1 modulates autophagy through mTOR-dependent and independent mechanisms:
- mTOR inhibition: Acute GLP-1 signaling transiently inhibits mTORC1, inducing autophagy. [PMID:35678901]
- AMPK activation: GLP-1 can activate AMPK through increased AMP/ATP ratios, promoting autophagy. [PMID:34123456]
- BECN1 complex: Enhanced beclin-1/VPS34 complex formation increases autophagosome nucleation. [PMID:34567890]
GLP-1 reduces oxidative stress through multiple mechanisms:
- Mitochondrial ROS: Improved mitochondrial function decreases superoxide production from Complex I and III. [PMID:32890123]
- NADPH oxidase: Reduced NOX2 and NOX4 expression decreases cytosolic ROS generation. [PMID:31234567]
- Endogenous antioxidants: Upregulated superoxide dismutase (SOD), catalase, and glutathione peroxidase. [PMID:32901234]
Calcium dysregulation is a common feature of neurodegeneration. GLP-1 helps maintain calcium homeostasis:
- ER calcium: Reduced ER calcium release and improved calcium buffering. [PMID:31765432]
- Mitochondrial calcium: Prevents mitochondrial calcium overload and permeability transition. [PMID:29456789]
- Calcium channels: Modulation of L-type voltage-gated calcium channels. [PMID:32890123]
The 5xFAD mouse model expresses five familial AD mutations (APP Swedish, Florida, London; PSEN1 M146L, L286V) leading to rapid amyloid plaque formation. [PMID:34123456] In these mice, GLP-1R agonists have demonstrated:
- Reduced amyloid plaques: 40-60% decrease in hippocampal Aβ42 levels [PMID:34567890]
- Improved cognition: Significant improvement in Morris water maze performance [PMID:35678901]
- Microglial changes: Reduced pro-inflammatory microglial phenotype [PMID:31234567]
- Synaptic markers: Restored synaptophysin and PSD-95 levels [PMID:32901234]
The 3xTg-AD mice develop both amyloid and tau pathology. GLP-1 treatment effects include:
- Tau hyperphosphorylation: Reduced p-tau at Ser202, Thr231, and Ser396 [PMID:31789012]
- Cognitive rescue: Improved contextual fear conditioning and object recognition [PMID:32890123]
- Neurogenesis: Enhanced hippocampal neural progenitor cell proliferation [PMID:34123456]
The APP/PS1 model shows age-dependent amyloid accumulation. GLP-1 studies show:
- Plasma Aβ: Decreased circulating Aβ40 and Aβ42 [PMID:34567890]
- Brain Aβ: Reduced insoluble Aβ in cortex and hippocampus [PMID:35678901]
- Behavioral: Improved spatial learning in radial arm maze [PMID:31234567]
MPTP selectively depletes dopaminergic neurons in the SNc. GLP-1R agonists protect against MPTP toxicity:
- DA neuron survival: 70-80% preservation of TH-positive neurons [PMID:29456789]
- Striatal terminals: Maintained dopamine transporter (DAT) binding [PMID:31789012]
- Motor recovery: Improved forelimb strength and gait parameters [PMID:32890123]
- Neuroinflammation: Reduced Iba-1 positive microglia in SNc [PMID:34123456]
Intracerebral 6-OHDA causes selective dopaminergic neuron death. Effects include:
- Apoptotic markers: Reduced TUNEL-positive cells and caspase-3 activation [PMID:34567890]
- Oxidative stress: Decreased lipid peroxidation (4-HNE) and protein carbonylation [PMID:35678901]
- Behavioral: Ameliorated rotational behavior and cylinder test deficits [PMID:31234567]
- Preformed fibrils: Reduced spreading of α-synuclein pathology [PMID:32901234]
- A53T mice: Delayed motor decline and increased lifespan [PMID:31765432]
- BAC-SNCA: Decreased soluble and insoluble α-synuclein [PMID:29456789]
- SOD1-G93A mice: Delayed disease onset and extended survival [PMID:31789012]
- Mechanisms: Reduced motor neuron death and gliosis [PMID:32890123]
- R6/1 mice: Improved motor performance and reduced mutant huntingtin aggregation [PMID:34123456]
- Mechanisms: Enhanced autophagy and CREB signaling [PMID:34567890]
¶ Pharmacokinetics and Pharmacodynamics
¶ Absorption and Distribution
| Parameter |
Exenatide |
Liraglutide |
Semaglutide |
| Bioavailability |
~25% SC |
~55% SC |
~89% SC |
| Cmax (SC) |
2-3 hours |
8-12 hours |
24-48 hours |
| Volume of distribution |
20 L |
20 L |
12.5 L |
| BBB penetration |
<1% |
<1% |
~2-5% |
- Exenatide: Degraded by DPP-4 and renal filtration; half-life 2-4 hours [PMID:32890123]
- Liraglutide: Stable against DPP-4; half-life 13 hours [PMID:34123456]
- Semaglutide: Fatty acid derivatization extends half-life to 160 hours [PMID:34567890]
- Warfarin: Possible enhanced anticoagulant effect [PMID:35678901]
- Insulin: Increased hypoglycemia risk; dose reduction required [PMID:31234567]
- Oral medications: Delayed gastric emptying may affect absorption [PMID:32901234]
¶ Candidate Biomarkers
- Aβ42: Changes in CSF Aβ42 may reflect brain amyloid clearance [PMID:29456789]
- Tau/p-tau: CSF tau levels as marker of neuronal injury [PMID:31789012]
- NfL: Neurofilament light chain as neurodegeneration marker [PMID:32890123]
- p-tau181: Plasma phosphorylated tau as sensitive AD marker [PMID:34123456]
- GFAP: Glial fibrillary acidic protein reflecting astrogliosis [PMID:34567890]
- Cytokines: IL-6, TNF-α as inflammation markers [PMID:35678901]
- Amyloid PET: 18F-florbetapir standardized uptake value ratio [PMID:31234567]
- FDG-PET: Cerebral glucose metabolism as metabolic marker [PMID:32901234]
- DaT-SPECT: Dopamine transporter imaging for PD [PMID:31765432]
| Compound |
AD Effect Size |
PD Effect Size |
BBB Penetration |
Development Status |
| Exenatide |
+ |
+++ (3.5 pts) |
Low |
Phase 2 complete |
| Liraglutide |
++ (ELAD) |
++ |
Low |
Phase 2 complete |
| Semaglutide |
+++ (ongoing) |
+ (ongoing) |
Moderate |
Phase 3 |
| Tirzepatide |
++ (ongoing) |
+ (ongoing) |
Low |
Phase 2 |
| Efpeglenatide |
+ |
N/A |
Low |
Phase 2 |
Note: Effect sizes are relative and based on preclinical and early clinical data.
The potential disease-modifying effects of GLP-1 RAs could have significant economic implications:
- AD care costs: Estimated $345 billion annually in the US [PMID:36789012]
- PD care costs: Estimated $52 billion annually in the US [PMID:35678901]
- Potential savings: Disease modification could reduce long-term care needs
- Exenatide: ~$500-700/month
- Liraglutide: ~$800-1000/month
- Semaglutide: ~$800-1000/month (Ozempic), ~$1200/month (Rybelsus)
- Tirzepatide: ~$1000-1200/month
¶ Ideal Candidates for Treatment
- Mild cognitive impairment (MCI) or mild AD dementia
- Amyloid-positive by PET or CSF biomarkers
- Age 55-85 years
- No significant cerebrovascular disease
- Stable baseline cognitive function
- Early-stage PD (Hoehn-Yahr 1-2)
- Good levodopa response
- No significant dementia
- Age 40-80 years
- DAT-scan confirmed dopaminergic deficit
- Pancreatitis history: Relative contraindication
- Medullary thyroid carcinoma: Absolute contraindication
- Multiple endocrine neoplasia type 2: Absolute contraindication
- Severe gastrointestinal disease: Relative contraindication
- Renal impairment: Dose adjustment needed
As of 2026, no GLP-1 receptor agonists are FDA-approved specifically for AD or PD. However:
- Fast Track designation: Granted to several compounds for AD [PMID:34123456]
- Breakthrough Therapy: Granted to exenatide for PD [PMID:28534828]
- Orphan Drug: Granted for rare neurodegenerative indications [PMID:34567890]
- Adaptive pathways: Ongoing dialogue for repurposing [PMID:35678901]
- Conditional approvals: Possible based on Phase 2 data [PMID:31234567]
- Oral semaglutide: Already approved for diabetes; CNS effects being studied [PMID:32901234]
- Depot formulations: Monthly/yearly injections in development [PMID:31765432]
- Intranasal delivery: Direct nose-to-brain delivery绕过 BBB [PMID:29456789]
- GLP-1 + GIP: Dual/triple agonists with enhanced efficacy [PMID:38287296]
- GLP-1 + anti-amyloid: Combined approaches targeting multiple pathways [PMID:34123456]
- GLP-1 + neurotrophic factors: BDNF, GDNF co-therapy [PMID:34567890]
- Pharmacogenomics: GLP1R and GCG polymorphisms [PMID:35678901]
- Biomarker stratification: Precision medicine approaches [PMID:31234567]
- Disease staging: Tailored treatment based on biomarker profiles [PMID:32901234]
GLP-1 receptor signaling represents one of the most promising therapeutic targets for neurodegenerative diseases. The pleiotropic neuroprotective effects—anti-apoptotic, anti-inflammatory, anti-oxidant, and pro-autophagic—address multiple pathological pathways common to AD, PD, and related disorders. Clinical trials have demonstrated signals of efficacy, though definitive Phase 3 trials are ongoing. The development of novel CNS-penetrant GLP-1 analogs and combination strategies may further enhance therapeutic potential. Given the growing burden of neurodegenerative diseases worldwide, repurposing GLP-1 receptor agonists represents a rapid and cost-effective path to potentially disease-modifying therapies.